drugset / Trial / NCT02572609

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

NCT02572609

Phase 1 Completed Boehringer Ingelheim
CrossoverOpen-labelTreatment

Summary

to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH \& Co. KG to Boehringer Ingelheim compared to ambroxol hydrochloride syrup (Mucosolvan® adult syrup), manufactured by Boehringer Ingelheim do Brasil Química e Farmacêutica Ltda.

Timeline

Start
2011-11
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambroxol Small molecule

Indications

No indication recorded.